Deep dives into clinical AI, regulatory strategy, platform architecture, and the future of medicine.
The 7.3-system reconciliation nightmare that plagues traditional CROs is not a process problem — it is an architectural one. Here is how we solved it.
Detecting adverse events 72 hours before manual review is not a feature — it is the minimum viable standard for AI-native clinical operations.
Why the entity that owns the specimen, the platform, and the submission is the only entity that can guarantee end-to-end data integrity.
Memorial Sloan Kettering Cancer Center selected myOnsite as its IND-authorized decentralized phlebotomy provider. Here is what that means for the field.
South Asian genomic architectures are absent from all major Western biobank reference populations. This is not a research gap — it is a patient safety crisis.
The average TMF inspection readiness at top-20 CROs is 42%. medinovAI delivers 98.7% — continuously, not just at inspection time.